Phase 2 N=20 Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=40 TAK-935 Multiple Rising Dose Study in Healthy Participants
Epilepsy
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) — 40.0; 0; 16.7; 83.3 percentage of participants
N/A N=21 Olopatadine Eye Drops and Allergy Skin Testing
Allergic Rhinitis · Allergic Conjunctivitis
Primary: The Difference in Area (cm2) of the Wheal Size in Histamine Skin Test Response During Treatment With Olopatadine Compared to Placebo. — 0.461; 0.464 cm2 — p=0.57
Phase 3 N=385 Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)
Otitis Media With Effusion in Children · Otitis Media Recurrent
Primary: Percentage of Subjects With Sustained Clinical Cure at Day 8 — 76.2; 71.8; 56.8 percentage of participants
Phase 4 N=183 Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy
Disorder of Knee · Anesthesia
Primary: Probability of Motor Block — 5; 20; 27 percentage of motor block
N/A N=314 Evaluating Perioperative Dexamethasone and the Risk of Bleeding in Tonsillectomy
Post-operative Hemorrhage
Primary: Number of Participants With Post-tonsillectomy Bleeding — 13; 17 participants — p=0.05
Phase 3 N=8 Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease
Gaucher Disease, Type 1
Primary: The Difference in Hemoglobin Concentration [g/dL] — 9.49; 11.44 g/dL
Phase 4 N=93 A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
Multiple Sclerosis · Relapsing-Remitting
Primary: Change From Baseline in Multiple Sclerosis Impact Scale-29 (MSIS-29) Psychological Score at Month 12 — 35.19; 30.48; -2.44; -3.04 units on a scale — p=0.9148
Phase 2 N=111 Sym004 in Patients With Advanced Solid Tumors
Metastatic Colorectal Cancer
Primary: Number of Participants With Adverse Events (AEs) — 20; 29; 13; 12 Participants
Phase 2 N=170 Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
Type 1 Diabetes
Primary: Event-Specific Survival Comparisons — 22; 8; 9; 1 Participants — p=0.01
Phase 4 N=69 ClosureFAST vs. Laser Ablation for the Treatment of GSV Disease: A Multicenter, Single-Blinded, Randomized Study.
Venous Reflux
Primary: Pain — 0.7; 1.9 units on a scale — p=<0.0001
Phase 3 N=742 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Diffuse Large B-cell Lymphoma
Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276
Phase 3 N=308 Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants
Hepatitis B
Primary: Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies — 100; 100; 100; 100 IU/mL
Phase 3 N=1,014 Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -0.89; -0.91 percentage of hemoglobin
Phase 4 N=25 VANOS Cream and Skin Barrier Function
Atopic Dermatitis
Primary: Change in Eczema Severity and Area Index — 6.01 units — p=<0.01